The short version

Five things, before anything else.

• The molecule is not the therapy. The schedule is. Gonadorelin and leuprolide — the prostate-cancer castration drug — are the same signal at the same receptor. What separates “stimulates the axis” from “chemically castrates the patient” is how often the receptor is occupied, not what the molecule is.
• The half-life is two to ten minutes. Terminal, ten to forty. The pump is not an inconvenience bolted onto the drug — the ninety-minute timer, the catheter, the intravenous-preferred route are all direct engineering answers to that number.
• The pump evidence is strong and should be respected. Live birth in 65.9% of treatments and ovulation in 96% of cycles in functional hypothalamic amenorrhoea. Spermatogenesis in 77–82% of men with congenital hypogonadotropic hypogonadism, reaching it about five months earlier than gonadotropins.
• The use it is actually sold for has no evidence at all. Subcutaneous bolus gonadorelin alongside testosterone, to preserve testicular function. We searched PubMed, PMC, ClinicalTrials.gov, the guideline literature and the sellers' own citation lists. No randomised trial. No controlled cohort. No retrospective series. No case report with hormone data. The AUA/ASRM male infertility guideline does not mention gonadorelin once.
• And unusually, it is not a legal grey area. A USP monograph exists for gonadorelin acetate. That satisfies the first prong of the compounding statute outright — which is more than can be said for almost any other peptide on this shelf.

What gonadorelin is

Ten residues, both ends blocked. It is the hormone itself — not an analogue, not a fragment, not a modification.

Gonadotropin-releasing hormone was isolated from porcine hypothalami and sequenced in the early 1970s by the Schally and Guillemin groups, work that took the 1977 Nobel Prize. Gonadorelin is that decapeptide, made synthetically, unchanged.

Both ends are capped, and that is the interesting part

Position 1 is pyroglutamate — a glutamine that has cyclised onto its own backbone. Position 10 is a glycinamide. So unlike most peptides, gonadorelin has no free N-terminal amine and no free C-terminal acid.

• The pyroglutamate blocks aminopeptidase attack. DPP-4, the enzyme that shreds sermorelin and every unprotected GHRH analogue, is simply not relevant here — there is no free amine for it to grip.
• The C-terminal glycinamide is required for receptor binding. Hydrolyse it to the free acid and you have an inactive impurity 0.98 Da heavier, hiding inside the parent's own isotope envelope. It is the single worst thing that can be in a gonadorelin vial and the hardest to see.

Signalling

Receptor occupancy activates phospholipase C, which drives IP₃ and DAG, intracellular calcium release and protein kinase C — and the gonadotroph synthesises and secretes LH and FSH. Upstream of the GnRH neuron sit the KNDy neurons (kisspeptin, neurokinin B, dynorphin) of the arcuate nucleus. Those are the actual pulse generator; the GnRH neuron is downstream of them.

One structural oddity with real consequences: the mammalian type-I GnRH receptor lacks a C-terminal cytoplasmic tail, which is why its desensitisation kinetics are unlike almost any other GPCR — and why the next section behaves the way it does.

The pulsatility paradox

The same molecule, at the same receptor, does opposite things depending only on how often it arrives. This is not a nuance. It is the organising principle of an entire drug class.

The experiment

Belchetz, Plant, Nakai, Keogh and Knobil, Science, 1978. Ovariectomised rhesus monkeys in which endogenous GnRH secretion had been abolished by radiofrequency lesioning of the medial basal hypothalamus — so the only GnRH in the animal was the GnRH the experimenters gave it.

The mechanism is receptor downregulation and gonadotroph desensitisation after an initial stimulatory phase. Continuous occupancy takes the receptor off the cell surface.

This is where the castration drugs came from

Every GnRH agonist — leuprolide, goserelin, triptorelin, buserelin, nafarelin, histrelin — is a GnRH analogue engineered for slow receptor dissociation and resistance to peptidases. Give one continuously and you get a flare first: LH up roughly tenfold, testosterone above baseline, peaking at two to four days. Then the receptors internalise, and by two to four weeks the patient is at castrate testosterone. That is the intended effect, and it is how advanced prostate cancer is treated.

Frequency is a second, separate axis

It is not only whether pulses arrive, but how fast. In perifused pituitary cells with pulse amplitude held fixed and only the interval varied:

The same directionality holds in humans: in GnRH-deficient men, stepping pulse frequency from every 120 minutes to 60 to 15 raised mean LH while FSH stayed flat.

The practical consequence, and it matters for the next section: slow, infrequent GnRH exposure is FSH-biased and LH-inefficient. A once-daily schedule is not simply “fewer pulses.” It sits far outside the frequency band that upregulates the receptor and drives LHβ transcription, and there is no dose that fixes a frequency problem.

The use it is actually sold for

This is the most important section on this page, and the shortest answer on it is the honest one: nobody has studied this.

What is being sold

Since human chorionic gonadotropin moved to biologic status and left traditional compounding, men's-health telehealth clinics and compounders have adopted gonadorelin as its replacement — prescribed subcutaneously, once or twice a day or a few times a week, alongside testosterone, to preserve testicular volume, endogenous production and fertility.

What we found when we went looking for the evidence

We searched PubMed and PubMed Central, ClinicalTrials.gov, the guideline literature, recent narrative and systematic reviews on testosterone-induced reproductive suppression, and the compounders' and clinics' own cited references.

Four independent confirmations that the gap is real, not a search failure

1. The registry is empty. The only gonadorelin-in-men study on ClinicalTrials.gov is NCT00493961 (Massachusetts General, completed 2009) — and its intervention was pulsatile GnRH via microinfusion pump every two hours in untreated men with Kallmann syndrome and idiopathic hypogonadotropic hypogonadism. Different delivery, different population, different question.

2. The guideline does not mention it. The AUA/ASRM Male Infertility Guideline (2020, amended 2024) names aromatase inhibitors, hCG and SERMs in Statement 41. Gonadorelin appears nowhere in the recommendations.

3. A 2025 review written about exactly this problem omits it. A Translational Andrology and Urology review on preserving spermatogenesis in men on testosterone covers intranasal testosterone, oral testosterone undecanoate, testosterone plus low-dose hCG, and enclomiphene. GnRH appears only in the pathophysiology paragraph. There is no treatment recommendation and no evidence grading for it, because there is nothing to grade.

4. The 2026 review that does discuss it, cites nothing. A Frontiers in Reproductive Health narrative review published in August 2026 says gonadorelin's efficacy “depends on physiological pulsatile administration,” that continuous exposure causes receptor downregulation, and that clinical use “remains limited by practical challenges related to pulsatile administration requirements.” It attaches no clinical evidence to the compound for this use.

The pharmacology argues against it, on four separate grounds

Taken together, the marketed schedule is the worst-case combination available: the shortest-acting agent, by the route that most blurs pulsatility, at the lowest frequency anyone has ever proposed.

The number that makes the route point concrete

In the pulsatile product's own registration programme, ovulation rates were near-identical by route — 72% intravenous against 70% subcutaneous. But pregnancy per treatment regimen was 19% intravenous against 7% subcutaneous. Nearly threefold, on delivery route alone, with the same drug and the same pulse schedule.

One study did test daily injections against the pump

Shargil, Fertility and Sterility, 1987: thirty men aged 24–35 with incomplete idiopathic hypogonadotropic hypogonadism, randomised between twice-daily subcutaneous injections and a pump pulsing every 90 minutes. The pump arm normalised hormones in two to three weeks and reached sperm counts above 60 million/mL by three to five months, with eighteen deliveries. The authors concluded the pump was superior and advocated pulsatile treatment. The injection schedule was not endorsed.

What can honestly be said

• It is biologically plausible in principle that a GnRH dose stimulates gonadotrophs — a single dose demonstrably raises LH for an hour or two. That is precisely what the diagnostic test measures.
• It is not established that one or two such spikes a day translate into preserved intratesticular testosterone, testicular volume or spermatogenesis in men whose axis is suppressed by exogenous testosterone.
• No published study has measured that endpoint. Anyone who claims otherwise should be asked for the citation, and the citation should be read — because the ones that get offered are pump studies in a different population.
• There is a theoretical risk running the other way, and it is also unstudied: chronic bolus exposure at non-physiological intervals could in principle contribute to gonadotroph desensitisation. There is no human data either way. That is unknown, not safe.

Credit where it is due: at least one clinic in this sector says so openly on its own website — that there is not enough evidence that an intermittent injection protocol reliably preserves fertility on testosterone, that most of the positive literature involves true pulsatile therapy in a different clinical situation, and that gonadorelin and hCG “should not be considered interchangeable medications.” That is an admission against interest, and it is correct.

What the pump actually achieved

The evidence that gets borrowed is worth reading on its own terms. It is good.

Ovulation induction

The approved indication was induction of ovulation in women with primary hypothalamic amenorrhoea due to deficient endogenous GnRH secretion — delivered by a worn pulsatile pump, one micro-dose every 90 minutes.

The modern dataset is a 25-year single-centre Swiss cohort: 66 patients with functional hypothalamic amenorrhoea, 82 treatments, 212 cycles.

By diagnosis, ovulation rates run above 90% per cycle in hypogonadotropic hypogonadism and 82–100% in hypothalamic amenorrhoea, but fall to 40–60% in polycystic ovary syndrome without agonist pretreatment. The mechanism is not universal.

Spermatogenesis in men

A meta-analysis of seven studies and 420 men with congenital hypogonadotropic hypogonadism compared pulsatile GnRH against gonadotropin therapy:

A 2025 single-centre cohort of 54 adult men on a pump at 16 pulses per 24 hours saw testosterone rise from 48 to 361 ng/dL at one year, testicular volume from 3.2 to 8.9 mL, and spermatogenesis in 79.4% at a mean of 6.5 months. Success split sharply by subgroup — 91.3% in normosmic disease against 54.5% in Kallmann syndrome, and 85.7% under age 28 against 50.0% at 28 and over.

Two limits worth stating. No randomised trial has ever compared pulsatile GnRH with gonadotropins for ovulation induction — the comparative data are retrospective. And pulsatile GnRH for spermatogenesis was never FDA-approved in the United States; its use there was confined to specialist centres, and the pulsatile product is no longer marketed in the US at all.

The stimulation test

The first approved use, and the one with the clearest published account of why it faded.

The diagnostic product was indicated for evaluating the functional capacity and reserve of the anterior pituitary gonadotrophs. A single dose, then seven venous samples for LH over two hours. Peak LH in men arrives at 34 ± 13 minutes subcutaneously, 27 ± 14 intravenously. Women in the early follicular phase peak later and far more variably — 71.5 ± 49.6 minutes subcutaneously.

The logic, and the flaw

A preserved response means the gonadotrophs are intact, pointing to a hypothalamic lesion. A blunted response points to a pituitary lesion. Neat — except that a chronically GnRH-deprived but structurally normal pituitary also fails to respond to a single bolus, mimicking pituitary disease exactly. Gonadotrophs need prior pulsatile priming to answer. That is section three read backwards, and it means one bolus cannot reliably separate the two compartments.

The number

The best modern dataset, Human Reproduction 2020, 232 males — 127 with congenital hypogonadotropic hypogonadism, 74 with constitutional delay of puberty, 31 controls:

The ranges overlap heavily. The authors concluded that both the GnRH test and inhibin B “lack specificity and sensitivity to efficiently discriminate” the two conditions, particularly in partial forms.

What replaced it

Three things converged. Ultrasensitive basal LH assays made the stimulation test unnecessary in much of paediatric precocious-puberty work. The test could not do its headline job reliably. And native gonadorelin stopped being easy to obtain, so centres substituted short-acting agonists.

Those substitutes are not numerically interchangeable, which is a real clinical problem rather than a footnote. In boys, a 2025 comparison found peak LH of 9.7 mIU/mL with gonadorelin, peaking at 45 minutes in 70% of cases, against 20.0 mIU/mL with triptorelin peaking at 90 minutes in 87%. Different magnitude, different kinetics, same cut-offs applied. The authors said triptorelin “shows limitations as a reliable alternative.”

The rest of the family, and why hCG is not the same thing

Gonadorelin is sold as an hCG substitute. They act on different receptors, in different tissues, with half-lives three orders of magnitude apart.

What hCG actually has behind it

This matters because gonadorelin inherits hCG's credibility in the buyer's mind. hCG has a dose-ranging study showing intratesticular testosterone rising linearly with dose during gonadotropin suppression, and a urology study reporting preserved spermatogenesis in men on testosterone. It is the agent named in the guideline. Gonadorelin is not.

For balance, hCG is not a solved problem either — the 2026 review notes it does not consistently restore spermatogenesis in every patient, and is limited by injection burden, raised estradiol, gynaecomastia, dosing variability and cost. And kisspeptin, the compound with the most human evidence among the emerging alternatives, has also never been evaluated in a large trial for testosterone-suppressed testicular function. Nobody has solved this.

Regulatory status, stated precisely

Gonadorelin's legal position is genuinely unusual, and it runs in the opposite direction from most peptides on this shelf.

The USP monograph is the interesting line

Under the compounding statute, a bulk substance qualifies if it satisfies any one of three prongs: it complies with an applicable USP or NF monograph; or it is a component of an FDA-approved drug; or it appears on the 503A bulks list.

Gonadorelin acetate has a USP monograph. The first prong is satisfied outright, and the other two are never reached. That is a materially stronger position than almost any other compound in this library — most of which have no monograph, no approved-drug component, and a place on a nominations list at best.

Worth naming the naming trap while we are here: search DailyMed for “Factrel” today and you get the cattle label — bovine ovarian follicular cysts, “For use in animals only. Not for human use.” It is not the human diagnostic product, and confusing the two is the single most likely factual error on any page about this compound.

Sport

Gonadorelin sits under WADA section S2.2.1, testosterone-stimulating peptides, which is restricted to males — an unusual construction, and one worth stating precisely rather than rounding off. Prohibited at all times, in and out of competition, and non-specified.

The enforcement precedent, and it is recent

Reconstitution and handling

Straightforward chemistry, with one storage instruction that is not optional.

Solubility

Water-soluble; roughly 10 mg/mL in phosphate-buffered saline at pH 7.2. Only two ionisable basic sites — Arg⁸ and His² — because both termini are blocked, so it is much less cationic than most peptides in this library. One widely-copied database entry lists gonadorelin as water-insoluble; that entry is wrong and the original label says “soluble in alcohol and water.”

Arithmetic for a 2 mg vial

Technique

1. Bring the vial to room temperature before piercing. The lyophilisate is hygroscopic, and moisture — not temperature — is the main enemy here.
2. Run the diluent down the glass wall, not onto the cake.
3. Swirl. Do not shake.
4. The solution should be clear and colourless. Anything else, reject the vial.

What the original pharmaceutical vial contained

The human diagnostic product was a lyophilised powder containing 100 mg of lactose USP as bulking agent — lactose, not mannitol — supplied with 2 mL of 2% benzyl alcohol in water as diluent, stored at room temperature, and used within one day of reconstitution.

The currently marketed veterinary aqueous product is the better real-world benchmark for in-use stability: 50 µg/mL in saline with 2% benzyl alcohol, stored 2–8 °C, with a one-month in-use period after first puncture. That is a regulator-reviewed figure for a preserved aqueous gonadorelin solution, which is more than exists for most peptides.

Storage, stability and what a certificate should show

Gonadorelin's blocked termini remove some common failure modes and introduce one that most peptides here do not have.

What degrades it, and where

In the body, three enzymes do the work: thimet oligopeptidase and neprilysin cut the Tyr⁵–Gly⁶ bond, prolyl endopeptidase cuts Pro⁹–Gly¹⁰-NH₂, and pyroglutamyl peptidase attacks the capped N-terminus. Hence the two-to-ten minute half-life.

In the vial, the picture is unusual. There is no asparagine and no glutamine, so the classical deamidation route that dominates most peptide stability simply does not exist here. There is no cysteine and no methionine. What remains:

• Tryptophan³ photo-oxidation — +16 or +32 Da. Tryptophan is the worst photo-labile residue there is, and gonadorelin has one. Protect from light is not boilerplate on this molecule.
• Histidine² oxidation — +16 Da.
• Base-catalysed hydrolysis of the C-terminal amide to the inactive free acid, +0.98 Da. Hold reconstituted solution around pH 4–5.
• An uncyclised Gln¹ open-chain form, +18 Da — material where the pyroglutamate never closed. It is invisible to amino acid analysis, because the residue composition is identical.

Storage

Reading a certificate

The analytical fingerprint is distinctive and easy to check. With only two basic sites and both termini blocked, the ESI charge envelope is compressed: the base peak is the doubly-charged ion near m/z 591.8, with the singly-charged ion near 1182.6 secondary. A 4+ or 5+ envelope means a mis-assignment or a different peptide in the vial.

Two more things worth insisting on. Ask for dual-wavelength detection at 220 and 280 nm — the ratio between them is a free, high-value check on tryptophan oxidation that costs the lab nothing. And ask for a shallow gradient: the des-amido free acid is only one dalton from the parent and will not resolve on a fast run.

One honest note on market quality data. The largest public survey of directly marketed research peptides — 6,285 samples across 203 manufacturers — covered fourteen compounds. We could not confirm gonadorelin was among them, so we are not quoting a figure for it. Where a number does not exist, we would rather say so than borrow one from a neighbouring compound.

Safety

Well tolerated in the studied uses. The one signal that matters points directly at the unstudied one.

From the registration programme

Overall adverse event incidence was around 10% of treatment regimens. Rare events (0.01–0.1%) included injection-site reddening, mild ovarian hyperstimulation and hypersensitivity. Very rare (under 0.01%) included anaphylactic shock, transient neurological symptoms, headache, nausea and abdominal pain. Pump-related problems — catheter inflammation, infection, mild phlebitis, haematoma — are a separate category that belongs to the device.

Hypersensitivity, and the direction of the risk

Bronchospasm, tachycardia, flushing, urticaria and induration are all reported. And the label is specific about the pattern:

Antibodies

Roughly 3% antibody formation after subcutaneous administration, reported over three weeks to nine months in 163 patients, with the note that “some cases appear to be related to a decreased effectiveness of the drug.” It is listed as a concern with long-term treatment specifically.

Ovarian hyperstimulation — a real advantage, mechanistically explained

Pulsatile GnRH leaves ovarian–pituitary negative feedback intact; exogenous gonadotropins bypass it. The registration programme reported one moderate case among 268 patients, and attributed the low incidence to preserved feedback. Mild hyperstimulation occurs in around 2.5% of pulsatile cycles against 3–7% hospitalisation with exogenous gonadotropins.

Multiple pregnancy — the literature does not agree, and we will say so

The spread probably reflects era, diagnosis mix and dose. Rates are consistently lower than with gonadotropins — but “monofollicular and therefore safe” oversimplifies the registration data, and the registration data are what the label was built on.

The absence

There is no long-term safety data for chronic daily subcutaneous gonadorelin in eugonadal or testosterone-treated men. That is a statement of absence and we publish it as one. Nobody has run it, because nobody has run any study of that use at all.

Questions we actually get

Is gonadorelin the same as hCG?

No, and it is not a substitute for it. hCG acts on the LH receptor on the Leydig cell and bypasses the pituitary completely. Gonadorelin acts on the pituitary and requires the pituitary to answer. Their half-lives differ by roughly three orders of magnitude. There is no comparative study between them for any indication.

Does it work alongside testosterone to preserve testicular function?

Nobody knows, because nobody has measured it. Not one published study of any design — no trial, no cohort, no case series with hormone data. If someone shows you a citation, read it: the ones that get offered are pump studies, delivering a micro-dose every ninety minutes, in men with congenital hypogonadotropic hypogonadism who were not on testosterone.

But isn't it more natural than hCG, because it works upstream?

The molecule is physiological. The schedule is not. Every physiological claim attached to gonadorelin belongs to pulsatile delivery. Deliver the same molecule continuously and it is a castration agent — that is not rhetoric, it is the 1978 experiment the entire GnRH agonist industry was built on.

Why does it need a pump?

Two to ten minute half-life. A single dose raises LH for about an hour and the diagnostic protocol stops sampling at two hours because the event is over. The body's own pulses run every 90 to 120 minutes, which is 12 to 16 a day. A pump is the only practical way to reproduce that with a molecule cleared in minutes. The pump is not an accessory to the drug. It is the drug's mechanism.

Is it legal to compound?

This is the one place gonadorelin is in a stronger position than most peptides. A USP monograph exists for gonadorelin acetate, which satisfies the first prong of the compounding statute on its own. It is not on any FDA do-not-compound list. Note that this is about the substance, not about any particular claim made when selling it — see the next answer.

Didn't the FDA just take action over this?

Yes. A warning letter in June 2026 named gonadorelin as an unapproved new drug and rejected “research use only” labelling, because the benefit claims in the surrounding copy showed human intent. The labelling was not the failure. The claims beside it were.

Is it banned in sport?

Yes — and unusually, in males only. Section S2.2.1 of the WADA list covers testosterone-stimulating peptides in males, GnRH and its agonist analogues included. Prohibited at all times, not just in competition.

How much water for a 2 mg vial?

2 mL gives 1 mg/mL and is the cleanest arithmetic. Solubility is not a constraint here.

So why do you list it?

Because it is one of the best-documented peptides in existence — a Nobel-winning molecule with an approved product history, a USP monograph, registration-quality safety data and decades of strong pump trials. It is also the clearest case we know of where excellent evidence is being transferred onto a completely different intervention. Both of those are worth writing down.

References

1. Belchetz PE, Plant TM, Nakai Y, Keogh EJ, Knobil E. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978;202(4368):631–633. DOI 10.1126/science.100883. PMID 100883. — the experiment this whole page rests on. Pulses stimulate; continuous suppresses; switching back restores.
2. Kaiser UB, et al. Differential effects of gonadotropin-releasing hormone pulse frequency on gonadotropin subunit and GnRH receptor messenger ribonucleic acid levels in vitro. Endocrinology 1997;138(3):1224–. — LHβ and receptor mRNA maximal at 30-minute intervals; FSHβ at two hours.
3. Quaas P, Quaas AM, Fischer M, De Geyter C. Use of pulsatile gonadotropin-releasing hormone in patients with functional hypothalamic amenorrhea results in monofollicular ovulation and high cumulative live birth rates: a 25-year cohort. J Assist Reprod Genet 2022. DOI 10.1007/s10815-022-02656-0. PMID 36378460. — 66 patients, 212 cycles. Live birth 65.9% per treatment, ovulation 96% per cycle, multiples 1.6%.
4. Wei C, Long G, Zhang Y, et al. Spermatogenesis of male patients with congenital hypogonadotropic hypogonadism receiving pulsatile gonadotropin-releasing hormone therapy versus gonadotropin therapy: a systematic review and meta-analysis. World J Mens Health 2020;39(4):654–665. DOI 10.5534/wjmh.200043. PMID 32777865. — 420 patients. Five months faster, no difference in sperm concentration or pregnancy, and significantly more allergic reactions.
5. Jiang H, Li BJ, Jin DC, et al. Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogonadism: a retrospective study. Transl Androl Urol 2025;14(7):2043–2058. DOI 10.21037/tau-2025-199. — 54 men, 16 pulses per 24 hours, spermatogenesis in 79.4%. Note the subgroup splits.
6. Shargil AA. Treatment of idiopathic hypogonadotropic hypogonadism in men with luteinizing hormone-releasing hormone: a comparison of treatment with daily injections and with the pulsatile infusion pump. Fertil Steril 1987;47(3):492–501. PMID 3549367. — the only study that ever put daily injections against the pump. The pump won.
7. Mosbah H, Bouvattier C, Maione L, et al. GnRH stimulation testing and serum inhibin B in males: insufficient specificity for discriminating between congenital hypogonadotropic hypogonadism from constitutional delay of growth and puberty. Hum Reprod 2020;35(10):2312–2322. DOI 10.1093/humrep/deaa185. PMID 32862222. — 232 males. Sensitivity 68.5% at the best threshold.
8. Seo JH, Yoo M-J, Lee K, et al. Is the triptorelin stimulation test comparable to the gonadorelin test in diagnosing central precocious puberty in boys? J Endocr Soc 2025;9(Suppl 1):bvaf149.1803. — different magnitude and different kinetics. And the plain statement that restricted gonadorelin availability drove the substitution.
9. Cretu A-M, Kamar AAM, Ciobica A, et al. Emerging peptide and neuroendocrine strategies for TRT-induced reproductive suppression and functional male hypogonadism: a narrative review. Front Reprod Health 2026;8:1914709. DOI 10.3389/frph.2026.1914709. PMID 42666625. — discusses gonadorelin and attaches no clinical evidence to it for this use.
10. Hochu G, Geyer-Kim I, Kim E. Preserving spermatogenesis in testosterone deficiency: innovations in replacement and stimulatory therapies. Transl Androl Urol 2025;14(12):3975–3987. DOI 10.21037/tau-2025-480. — a review written about exactly this problem that does not mention gonadorelin as a treatment at all.
11. American Urological Association / American Society for Reproductive Medicine. Diagnosis and Treatment of Infertility in Men: AUA/ASRM Guideline (2020, amended 2024). — Statement 41 names aromatase inhibitors, hCG and SERMs. Gonadorelin appears nowhere.
12. Hsieh T, Pastuszak AW, Hwang K, Lipshultz LI. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol 2013;189(2):647–650. DOI 10.1016/j.juro.2012.09.043. PMID 23260550. — the hCG counterfactual, and the reason hCG is in the guideline.
13. Fredrick JR, et al. Hypogonadotropic Hypogonadism and Gonadotropin Therapy, and Physiology of GnRH and Gonadotrophin Secretion. In: Endotext. NCBI Bookshelf NBK279078 and NBK279070. — the source of the comparative verdict: no advantage of either therapy on final sperm counts or pregnancy rates.
14. Global Library of Women's Medicine. The Use of Gonadotropin-Releasing Hormone to Induce Ovulation. — the route comparison, the diagnosis-by-diagnosis ovulation rates, and the statement that no randomised trial has ever compared pulsatile GnRH with gonadotropins.
15. Lutrepulse (gonadorelin acetate) product monograph, Ferring, 17 May 2016; and Factrel (gonadorelin hydrochloride) US prescribing information. — the source of the pharmacokinetics, the registration-trial route split (19% IV vs 7% SC), the adverse-event rates, the antibody figure, and the LH peak timing.
16. United States Pharmacopeia. Gonadorelin Acetate, USP–NF monograph M35780, official 2017; and the gonadorelin hydrochloride monograph. — the monograph that settles the compounding question.
17. US Food and Drug Administration. Warning letter, 17 June 2026 (MARCS-CMS 729447). — names gonadorelin, and rejects research-use-only labelling where surrounding copy evidences human intent.
18. Health Canada. Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks. Alert RA-77807, 1 August 2025. — gonadorelin is named in the affected-products list.
19. World Anti-Doping Agency. The 2026 Prohibited List, section S2.2.1, testosterone-stimulating peptides in males. — note the male-only restriction, which is unusual and often reported incorrectly.

Research-use compound. This page reports what the published literature and the regulatory record contain. It is not medical advice, it is not a protocol, and nothing on it should be read as a recommendation for use in humans.